Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
75,239 questions in 5,342 reviews
current versionsNo studies 15,213 · 20.2%Ungraded 10,323 · 13.7%Very low 17,528 · 23.3%Low 17,951 · 23.9%Moderate 11,190 · 14.9%High 3,034 · 4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Corticosteroids vs placebo Caloric extent of recovery (improvement as a % in lateralisation of electronystagmography on caloric testing) · Patients with idiopathic acute vestibular dysfunction (vestibular neuritis) Corticosteroids for the treatment of idiopathic acute vestibular dysfunction (vestibular neuritis) (2011) · Cochrane | no estimate extracted | 2 studies · 89 participants | Low |
Corticosteroids vs placebo Complete caloric recovery · Patients with idiopathic acute vestibular dysfunction (vestibular neuritis) Corticosteroids for the treatment of idiopathic acute vestibular dysfunction (vestibular neuritis) (2011) · Cochrane | RR 2.81 [1.32, 6] | 2 studies · 50 participants | Low |
Corticosteroids vs placebo Complete caloric recovery · Patients with idiopathic acute vestibular dysfunction (vestibular neuritis) Corticosteroids for the treatment of idiopathic acute vestibular dysfunction (vestibular neuritis) (2011) · Cochrane | RR 1.58 [0.45, 5.62] | 2 studies · 89 participants | Low |
Corticosteroids vs placebo Adverse effects · Patients with idiopathic acute vestibular dysfunction (vestibular neuritis) Corticosteroids for the treatment of idiopathic acute vestibular dysfunction (vestibular neuritis) (2011) · Cochrane | no estimate extracted | 1 study · 73 participants | Moderate |
Intervention NR Cure · prevention and treatment of vulvovaginal candidiasis in women with HIV infection Interventions for prevention and treatment of vulvovaginal candidiasis in women with HIV infection (2011) · Cochrane | RR 0 [0, 0] | 0 studies · 1 participants | Ungraded |
Lactobacillus vs Placebo Cure · patients with prevention and treatment of vulvovaginal candidiasis in women with HIV infection Interventions for prevention and treatment of vulvovaginal candidiasis in women with HIV infection (2011) · Cochrane | RR 0 [0, 0] | 0 studies · 0 participants | Ungraded |
Lactobacillus vs Placebo Episodes of confirmed vaginal candidiasis fungal smear · patients with prevention and treatment of vulvovaginal candidiasis in women with HIV infection Interventions for prevention and treatment of vulvovaginal candidiasis in women with HIV infection (2011) · Cochrane | RR 0.54 [0.26, 1.13] | 1 study · 114 participants | Low |
Clotrimazole vs Placebo Cure · patients with prevention and treatment of vulvovaginal candidiasis in women with HIV infection Interventions for prevention and treatment of vulvovaginal candidiasis in women with HIV infection (2011) · Cochrane | RR 0 [0, 0] | 0 studies · 0 participants | Ungraded |
Clotrimazole vs Placebo Episode of confirmed vaginal candidiasis fungal smear · patients with prevention and treatment of vulvovaginal candidiasis in women with HIV infection Interventions for prevention and treatment of vulvovaginal candidiasis in women with HIV infection (2011) · Cochrane | RR 0.49 [0.22, 1.09] | 1 study · 106 participants | Low |
Azoles vs Placebo Episode of confirmed vaginal candidiasis Fungal Smears · patients with prevention and treatment of vulvovaginal candidiasis in women with HIV infection Interventions for prevention and treatment of vulvovaginal candidiasis in women with HIV infection (2011) · Cochrane | RR 0.63 [0.46, 0.88] | 2 studies · 429 participants | Very low |
Intervention NR Episode of confirmed vaginal candidiasis ‐ Upto 12 months Fungal smears · prevention and treatment of vulvovaginal candidiasis in women with HIV infection Interventions for prevention and treatment of vulvovaginal candidiasis in women with HIV infection (2011) · Cochrane | RR 0.68 [0.47, 0.97] | 1 study · 323 participants | Moderate |
Intervention NR Episode of confirmed vaginal candidiasis ‐ Upto 24 Months Fungal smears · prevention and treatment of vulvovaginal candidiasis in women with HIV infection Interventions for prevention and treatment of vulvovaginal candidiasis in women with HIV infection (2011) · Cochrane | RR 0.79 [0.63, 0.99] | 1 study · 323 participants | Moderate |
Intervention NR Emergence of non albicans species of Candida ‐ At 12 months Fungal Smears · prevention and treatment of vulvovaginal candidiasis in women with HIV infection Interventions for prevention and treatment of vulvovaginal candidiasis in women with HIV infection (2011) · Cochrane | RR 1.46 [0.85, 2.51] | 1 study · 323 participants | Moderate |
Intervention NR Emergence of non albicans species of Candida ‐ At 24 months Fungal Smears · prevention and treatment of vulvovaginal candidiasis in women with HIV infection Interventions for prevention and treatment of vulvovaginal candidiasis in women with HIV infection (2011) · Cochrane | RR 1.32 [0.89, 1.94] | 1 study · 323 participants | Moderate |
Intervention NR In Vitro resistance to azoles ‐ Candida albicans MIC >= 64 micrograms/ml · prevention and treatment of vulvovaginal candidiasis in women with HIV infection Interventions for prevention and treatment of vulvovaginal candidiasis in women with HIV infection (2011) · Cochrane | RR 0.86 [0.15, 4.9] | 1 study · 96 participants | Moderate |
Intervention NR In Vitro resistance to azoles ‐ Non albicans Candida MIC>= 64 micrograms/ml · prevention and treatment of vulvovaginal candidiasis in women with HIV infection Interventions for prevention and treatment of vulvovaginal candidiasis in women with HIV infection (2011) · Cochrane | RR 5.57 [1.7, 18.29] | 1 study · 96 participants | Moderate |
Lactobacillus vs Clotrimazole Cure · prevention and treatment of vulvovaginal candidiasis in women with HIV infection Interventions for prevention and treatment of vulvovaginal candidiasis in women with HIV infection (2011) · Cochrane | RR 0 [0, 0] | 0 studies · 0 participants | Ungraded |
Lactobacillus vs Clotrimazole Episodes of confirmed vaginal candidiasis fungal smear · prevention and treatment of vulvovaginal candidiasis in women with HIV infection Interventions for prevention and treatment of vulvovaginal candidiasis in women with HIV infection (2011) · Cochrane | RR 1.11 [0.45, 2.76] | 1 study · 108 participants | Low |
Intervention NR Pulmonary Methotrexate pneumonitis · patients with inflammatory arthritis on methotrexate Safety of non‐steroidal anti‐inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people… (2011) · Cochrane | no estimate extracted | 2 studies · 27 participants | Moderate |
Intervention NR Hepatic Liver histology/hepatic enzyme abnormalities2 · patients with inflammatory arthritis on methotrexate Safety of non‐steroidal anti‐inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people… (2011) · Cochrane | no estimate extracted | 2 studies · 272 participants | Low |
Intervention NR Renal Glomerular and tubular injury · patients with inflammatory arthritis on methotrexate Safety of non‐steroidal anti‐inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people… (2011) · Cochrane | no estimate extracted | 2 studies · 30 participants | Low |
Intervention NR Haematological Thrombocytopenia · patients with inflammatory arthritis on methotrexate Safety of non‐steroidal anti‐inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people… (2011) · Cochrane | no estimate extracted | 0 studies · 1 participants | Moderate |
Intervention NR Withdrawal due to adverse events Methotrexate discontinuation · patients with inflammatory arthritis on methotrexate Safety of non‐steroidal anti‐inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people… (2011) · Cochrane | no estimate extracted | 3 studies · 632 participants | Low |
Intervention NR All adverse events · patients with inflammatory arthritis on methotrexate Safety of non‐steroidal anti‐inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people… (2011) · Cochrane | no estimate extracted | 7 studies · 283 participants | Moderate |
Tricyclic antidepressant vs control Pain < 1 week VAS scale 0 to 100 mm · patients with pain management in RA Antidepressants for pain management in rheumatoid arthritis (2011) · Cochrane | no estimate extracted | 1 study · 30 participants | Very low |
Tricyclic antidepressant vs control Pain 1 to 6 weeks Any pain measurement scale · patients with pain management in RA Antidepressants for pain management in rheumatoid arthritis (2011) · Cochrane | no estimate extracted | 7 studies · 482 participants | Very low |
Tricyclic antidepressant vs control Pain > 6 weeks Any pain measurement scale · patients with pain management in RA Antidepressants for pain management in rheumatoid arthritis (2011) · Cochrane | no estimate extracted | 5 studies · 368 participants | Very low |
Tricyclic antidepressant vs control Functional Status Health Assessment Questionnaire (HAQ) scale 0 to 3 · patients with pain management in RA Antidepressants for pain management in rheumatoid arthritis (2011) · Cochrane | no estimate extracted | 1 study · 28 participants | Low |
Tricyclic antidepressant vs control Number of Withdrawals due to Adverse Events patient interview · patients with pain management in RA Antidepressants for pain management in rheumatoid arthritis (2011) · Cochrane | RR 0.98 [0.59, 1.64] | 6 studies · 455 participants | Very low |
Tricyclic antidepressant vs control Total number of adverse events patient interview · patients with pain management in RA Antidepressants for pain management in rheumatoid arthritis (2011) · Cochrane | RR 1.83 [1.01, 3.3] | 6 studies · 455 participants | Very low |
Intervention vs control 60‐day mortality ‐ Aprotinin versus control · Patients with liver transplantation. Methods to decrease blood loss and transfusion requirements for liver transplantation (2011) · Cochrane | RR 0.52 [0.18, 1.45] | 3 studies · 280 participants | Very low |
Intervention vs control Thromboembolic episodes ‐ Recombinant factor VIIa (rFVIIa) versus control · Patients with liver transplantation. Methods to decrease blood loss and transfusion requirements for liver transplantation (2011) · Cochrane | RR 1.38 [0.65, 2.91] | 2 studies · 266 participants | Very low |
Intervention vs control Serious adverse events ‐ Recombinant factor VIIa (rFVIIa) versus control · Patients with liver transplantation. Methods to decrease blood loss and transfusion requirements for liver transplantation (2011) · Cochrane | RR 1.3 [0.94, 1.78] | 2 studies · 266 participants | Very low |
Intervention vs control Blood loss ‐ Aprotinin versus control (litre) · Patients with liver transplantation. Methods to decrease blood loss and transfusion requirements for liver transplantation (2011) · Cochrane | no estimate extracted | 3 studies · 195 participants | Very low |
Intervention vs control Blood loss ‐ Tranexamic acid versus control (litre) · Patients with liver transplantation. Methods to decrease blood loss and transfusion requirements for liver transplantation (2011) · Cochrane | no estimate extracted | 2 studies · 65 participants | Very low |
Intervention vs control Blood loss ‐ Thromboelastography versus control (litre) · Patients with liver transplantation. Methods to decrease blood loss and transfusion requirements for liver transplantation (2011) · Cochrane | no estimate extracted | 2 studies · 62 participants | Very low |
Intervention vs control Blood loss ‐ Tranexamic acid versus aprotinin · Patients with liver transplantation. Methods to decrease blood loss and transfusion requirements for liver transplantation (2011) · Cochrane | no estimate extracted | 2 studies · 71 participants | Very low |
Intervention vs control Red cell or whole blood transfusion ‐ Aprotinin versus control · Patients with liver transplantation. Methods to decrease blood loss and transfusion requirements for liver transplantation (2011) · Cochrane | no estimate extracted | 8 studies · 375 participants | Very low |
Intervention vs control Red cell or whole blood transfusion ‐ Tranexamic acid versus control · Patients with liver transplantation. Methods to decrease blood loss and transfusion requirements for liver transplantation (2011) · Cochrane | no estimate extracted | 4 studies · 159 participants | Very low |
Intervention vs control Red cell or whole blood transfusion ‐ Recombinant factor VIIa (rFVIIa) versus control · Patients with liver transplantation. Methods to decrease blood loss and transfusion requirements for liver transplantation (2011) · Cochrane | no estimate extracted | 2 studies · 221 participants | Very low |
Intervention vs control Red cell or whole blood transfusion ‐ Thromboelastography versus control · Patients with liver transplantation. Methods to decrease blood loss and transfusion requirements for liver transplantation (2011) · Cochrane | no estimate extracted | 2 studies · 62 participants | Very low |
Intervention vs control 60‐day mortality ‐ Tranexamic acid versus control · Patients with liver transplantation. Methods to decrease blood loss and transfusion requirements for liver transplantation (2011) · Cochrane | RR 0.55 [0.17, 1.76] | 3 studies · 139 participants | Very low |
Intervention vs control Red cell or whole blood transfusion ‐ Tranexamic acid versus aprotinin · Patients with liver transplantation. Methods to decrease blood loss and transfusion requirements for liver transplantation (2011) · Cochrane | no estimate extracted | 3 studies · 198 participants | Very low |
Intervention vs control 60‐day mortality ‐ Recombinant factor VIIa (rFVIIa) versus control · Patients with liver transplantation. Methods to decrease blood loss and transfusion requirements for liver transplantation (2011) · Cochrane | RR 1.51 [0.33, 6.95] | 3 studies · 286 participants | Very low |
Intervention vs control 60‐day mortality ‐ Tranexamic acid versus aprotinin · Patients with liver transplantation. Methods to decrease blood loss and transfusion requirements for liver transplantation (2011) · Cochrane | RR 4.12 [0.71, 23.76] | 2 studies · 178 participants | Very low |
Intervention vs control Primary graft non‐function ‐ Aprotinin versus control · Patients with liver transplantation. Methods to decrease blood loss and transfusion requirements for liver transplantation (2011) · Cochrane | RR 0.15 [0.02, 1.25] | 2 studies · 217 participants | Very low |
Intervention vs control Retransplantation ‐ Aprotinin versus control · Patients with liver transplantation. Methods to decrease blood loss and transfusion requirements for liver transplantation (2011) · Cochrane | RR 0.21 [0.02, 1.79] | 2 studies · 217 participants | Very low |
Intervention vs control Retransplantation ‐ Tranexamic acid versus control · Patients with liver transplantation. Methods to decrease blood loss and transfusion requirements for liver transplantation (2011) · Cochrane | RR 0.79 [0.18, 3.48] | 2 studies · 77 participants | Very low |
Intervention vs control Thromboembolic episodes ‐ Aprotinin versus control · Patients with liver transplantation. Methods to decrease blood loss and transfusion requirements for liver transplantation (2011) · Cochrane | RR 0.6 [0.18, 1.96] | 3 studies · 280 participants | Very low |
Intervention vs control Thromboembolic episodes ‐ Tranexamic acid versus control · Patients with liver transplantation. Methods to decrease blood loss and transfusion requirements for liver transplantation (2011) · Cochrane | RR 2.2 [0.38, 12.64] | 5 studies · 179 participants | Very low |